Disease · MONDO_0007039
Targets14
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
1 to 14 of 14
Download this page as JSON| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| EGFR | Epidermal growth factor receptor | 2 | Epidermal growth factor receptor erbB1 inhibitor | Phase 2 | https://conductscience.org/library/genes/1956 | Drugs and targets |
| ALK | ALK tyrosine kinase receptor | 1 | ALK tyrosine kinase receptor inhibitor; EML4-ALK inhibitor; NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) inhibitor | Phase 2 | https://conductscience.org/library/genes/238 | Drugs and targets |
| DHODH | Dihydroorotate dehydrogenase (quinone), mitochondrial | 1 | Dihydroorotate dehydrogenase inhibitor | Phase 2 | https://conductscience.org/library/genes/1723 | Drugs and targets |
| EML4 | EML4-ALK | 1 | EML4-ALK inhibitor | Phase 2 | https://conductscience.org/library/genes/27436 | Drugs and targets |
| ERBB2 | Receptor tyrosine-protein kinase erbB-2 | 1 | Receptor protein-tyrosine kinase erbB-2 inhibitor | Phase 2 | https://conductscience.org/library/genes/2064 | Drugs and targets |
| FKBP1A | Peptidyl-prolyl cis-trans isomerase FKBP1A | 1 | FK506-binding protein 1A inhibitor | Phase 2 | https://conductscience.org/library/genes/2280 | Drugs and targets |
| FLT1 | Vascular endothelial growth factor receptor | 1 | Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/2321 | Drugs and targets |
| FLT4 | Vascular endothelial growth factor receptor | 1 | Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/2324 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor | 1 | Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| MET | Hepatocyte growth factor receptor | 1 | Hepatocyte growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/4233 | Drugs and targets |
| MST1R | Macrophage-stimulating protein receptor | 1 | Macrophage-stimulating protein receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/4486 | Drugs and targets |
| NPM1 | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) | 1 | NPM/ALK (Nucleophosmin/ALK tyrosine kinase receptor) inhibitor | Phase 2 | https://conductscience.org/library/genes/4869 | Drugs and targets |
| ROS1 | Proto-oncogene tyrosine-protein kinase ROS | 1 | Proto-oncogene tyrosine-protein kinase ROS inhibitor | Phase 2 | https://conductscience.org/library/genes/6098 | Drugs and targets |
| VEGFA | Vascular endothelial growth factor A, long form | 1 | Vascular endothelial growth factor A inhibitor | Phase 2 | https://conductscience.org/library/genes/7422 | Drugs and targets |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0007039/targets